BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12393433)

  • 1. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
    Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
    Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
    Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice.
    Kroon E; Thorsteinsdottir U; Mayotte N; Nakamura T; Sauvageau G
    EMBO J; 2001 Feb; 20(3):350-61. PubMed ID: 11157742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
    Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
    Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.
    Matte-Martone C; Venkatesan S; Tan HS; Athanasiadis I; Chang J; Pavisic J; Shlomchik WD
    J Immunol; 2011 Aug; 187(4):1653-63. PubMed ID: 21768400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia with t(7;11)(p15;p15).
    Yamamoto K; Nakamura Y; Saito K; Furusawa S
    Br J Haematol; 2000 May; 109(2):423-6. PubMed ID: 10848835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of chronic myeloid leukemia progression.
    Sloma I; Beer P; Desterke C; Bulaeva E; Bilenky M; Carles A; Moksa M; Raghuram K; Brimacombe C; Lambie K; Turhan AG; Wagner-Ballon O; Gaulard P; Humphries K; Hirst M; Eaves CJ
    Haematologica; 2021 Mar; 106(3):881-885. PubMed ID: 32499242
    [No Abstract]   [Full Text] [Related]  

  • 12. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
    Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
    Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NUP98-HOXA9-transgenic zebrafish develop a myeloproliferative neoplasm and provide new insight into mechanisms of myeloid leukaemogenesis.
    Forrester AM; Grabher C; McBride ER; Boyd ER; Vigerstad MH; Edgar A; Kai FB; Da'as SI; Payne E; Look AT; Berman JN
    Br J Haematol; 2011 Oct; 155(2):167-81. PubMed ID: 21810091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical chronic myeloid leukemia harboring NUP98-HOXA9.
    Murayama H; Matsushita H; Ando K
    Int J Hematol; 2013 Aug; 98(2):143-4. PubMed ID: 23754767
    [No Abstract]   [Full Text] [Related]  

  • 18. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
    de Fabritiis P; Petti MC; Montefusco E; De Propris MS; Sala R; Bellucci R; Mancini M; Lisci A; Bonetto F; Geiser T; Calabretta B; Mandelli F
    Blood; 1998 May; 91(9):3156-62. PubMed ID: 9558370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia.
    Ahuja HG; Popplewell L; Tcheurekdjian L; Slovak ML
    Genes Chromosomes Cancer; 2001 Apr; 30(4):410-5. PubMed ID: 11241795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
    Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
    J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.